The Pharma Data

Faeth Therapeutics Appoints Debbie Chirnomas, M.D., M.P.H., as Chief Medical Officer

Faeth Therapeutics Appoints Debbie Chirnomas, M.D., M.P.H., as Chief Medical Officer –Faeth Therapeutics, a clinical-stage biotechnology company targeting cancer metabolism, today announced the appointment of Debbie Chirnomas M.D., M.P.H., as Chief Medical Officer. Dr. Chirnomas will head up the early…

Read MoreFaeth Therapeutics Appoints Debbie Chirnomas, M.D., M.P.H., as Chief Medical Officer

Cimeio Therapeutics Announces Publication of Seminal Epitope Editing Work in the Journal of Experimental Medicine

Cimeio Therapeutics Announces Publication of Seminal Epitope Editing Work in the Journal of Experimental Medicine Cimeio Therapeutics, a biotechnology company that is reimagining immunotherapy with its Shielded Cell and Immunotherapy (SCIP®) platform, along with Prof. Lukas Jeker’s team at the Department…

Read MoreCimeio Therapeutics Announces Publication of Seminal Epitope Editing Work in the Journal of Experimental Medicine

United Therapeutics Announces Recent Milestones for its Heart and Kidney Xenotransplantation Programs

United Therapeutics Announces Recent Milestones for its Heart and Kidney Xenotransplantation Programs United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced the achievement of two milestones for its xenotransplantation programs in September: the second transplant of a UHeart™ xenoheart…

Read MoreUnited Therapeutics Announces Recent Milestones for its Heart and Kidney Xenotransplantation Programs

Thought leaders at the Zayed Prize for Sustainable Development Forum chart paths forward to promote progress for people and planet

Thought leaders at the Zayed Prize for Sustainable Development Forum chart paths forward to promote progress for people and planet The Zayed Prize for Sustainable Development, the UAE’s pioneering prize for sustainable and humanitarian development, held its second forum in…

Read MoreThought leaders at the Zayed Prize for Sustainable Development Forum chart paths forward to promote progress for people and planet

Ligand’s Partner Jazz Pharmaceuticals Receives European Commission Approval for Enrylaze® (a recombinant Erwinia asparaginase or crisantaspase) for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

Ligand’s Partner Jazz Pharmaceuticals Receives European Commission Approval for Enrylaze® (a recombinant Erwinia asparaginase or crisantaspase) for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Ligand Pharmaceuticals Incorporated announced that its partner Jazz Pharmaceuticals plc (Nasdaq: JAZZ), (“Jazz”) has been…

Read MoreLigand’s Partner Jazz Pharmaceuticals Receives European Commission Approval for Enrylaze® (a recombinant Erwinia asparaginase or crisantaspase) for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

Datopotamab deruxtecan demonstrated a statistically significant and clinically meaningful progression-free survival benefits in patients with HR-positive, HER2-low, or negative breast cancer in the TROPION-Breast01 Phase III trial

Datopotamab deruxtecan demonstrated statistically significant and clinically meaningful progression-free survival benefit in patients with HR-positive, HER2-low, or negative breast cancer in TROPION-Breast01 Phase III trial Positive high-level results from the TROPION-Breast01 Phase III trial showed datopotamab deruxtecan (Dato-DXd) demonstrated a statistically…

Read MoreDatopotamab deruxtecan demonstrated a statistically significant and clinically meaningful progression-free survival benefits in patients with HR-positive, HER2-low, or negative breast cancer in the TROPION-Breast01 Phase III trial

Bristol Myers Squibb Announces Perioperative Regimen of Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo Significantly Improves Event-Free Survival in Patients with Resectable Non-Small Cell Lung Cancer

Bristol Myers Squibb Announces Perioperative Regimen of Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo Significantly Improves Event-Free Survival in Patients with Resectable Non-Small Cell Lung Cancer Bristol Myers Squibb today announced the Phase 3 CheckMate -77T trial met its primary endpoint of…

Read MoreBristol Myers Squibb Announces Perioperative Regimen of Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo Significantly Improves Event-Free Survival in Patients with Resectable Non-Small Cell Lung Cancer

Merck and Eisai Provide Update on Two Phase 3 Trials Evaluating KEYTRUDA Plus LENVIMA in Patients With Certain Types of Metastatic Non-Small Cell Lung Cancer

Merck and Eisai Provide Update on Two Phase 3 Trials Evaluating KEYTRUDA® (pembrolizumab Plus LENVIMA® (lenvatinib) in Patients With Certain Types of Metastatic Non-Small Cell Lung Cancer Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai…

Read MoreMerck and Eisai Provide Update on Two Phase 3 Trials Evaluating KEYTRUDA Plus LENVIMA in Patients With Certain Types of Metastatic Non-Small Cell Lung Cancer

Vividion Therapeutics starts Phase I clinical trial in advanced solid tumors with KEAP1 activator

Vividion Therapeutics starts Phase I clinical trial in advanced solid tumors with KEAP1 activator Vividion Therapeutics, Inc. (Vividion), announced today that it has initiated dosing of patients in a Phase I oncology clinical trial of its investigational oral Kelch-like ECH…

Read MoreVividion Therapeutics starts Phase I clinical trial in advanced solid tumors with KEAP1 activator